Other languages PYC Therapeutics Limited

Equities

PYC

AU000000PYC7

Market Closed - Australian S.E. Other stock markets 07:10:44 26/04/2024 BST			5-day change	1st Jan Change
0.092 ^AUD	-1.08%		+1.10%	-16.36%

04-22	Australian Shares Rebound Amid Easing Middle East Tensions, Ahead of Local Inflation Data	MT
04-22	PYC Therapeutics Confirms Safety, Tolerability of Kidney Medication in Animal Study	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Australian Shares Rebound Amid Easing Middle East Tensions, Ahead of Local Inflation Data	04-22
PYC Therapeutics Raises AU$13.5 Million via Retail Offer; AU$21.2 Million Retail Shortfall Placement Announced	04-10
PYC Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-29
PYC Therapeutics Receives AU$4.5 Million Upfront Fee for Drug Discovery Collaboration	02-16
PYC Therapeutics to Launch Google Cloud-Hosted Drug Discovery Project; Shares Fall 5%	01-02
Pyc Therapeutics Announces the Results of A Study Conducted in Human 3-Dimensional Models Derived from Patients with End-Stage Renal Failure Due to Autosomal Dominant Polycystic Kidney Disease	11-13
PYC Therapeutics Completes Dosing in Second Patient Cohort for Retinitis Pigmentosa Clinical Trial	11-03
PYC Reports Positive Results from Preclinical Studies of Rare Eye Disease Drug	05/10/23
PYC Therapeutics Advances to Second Dose Cohort of Phase 1 Trial Following Safety Clearance	22/09/23
PYC Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	31/08/23
PYC Therapeutics Limited Announces US FDA Designates PYC's Lead as a Fast Track Development Program	11/08/23
PYC Therapeutics' RP11 Investigational Drug Candidate Secures Fast Track Designation from US FDA; Shares Climb 3%	02/08/23
PYC Therapeutics Doses First Patient in Blinding Eye Disease Trial	30/06/23
Pyc Appoints Andrew Taylor as Joint Company Secretary	01/06/23
PYC Therapeutics to Raise AU$30 Million in Placement	11/05/23
PYC Therapeutics Secures US FDA Clearance to Start Retinitis Pigmentosa Trial	06/03/23
Us Fda Clears PYC Therapeutics Limited to Commence the First Ever Human Trial in Retinitis Pigmentosa Type 11	05/03/23
PYC Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2022	28/02/23
PYC Therapeutics Files IND Application with US FDA for Retinitis Pigmentosa Medication	02/02/23
PYC Therapeutics Limited Announces the Submission of Investigational New Drug Application with the US Food and Drug Administration	01/02/23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages PYC Therapeutics Limited

Equities

PYC

AU000000PYC7

Other languages

Filters